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Objective: To investigate resource use and time investments of healthcare professionals, patients and
their family and to compare healthcare and societal costs of one single hospital-based and one single
home-based subcutaneous administration of trastuzumab in The Netherlands.
Method: We conducted a bottom-up micro-costing study. Patients diagnosed with HER2þ early or
metastatic breast cancer were recruited in four Dutch hospitals. For healthcare costs, data were collected
on drug use, consumables, use of healthcare facilities, time of healthcare professionals, and travelling
distance of the nurse. For societal costs, data were collected on patient and family costs (including
travelling expenses and time of informal caregivers) and productivity losses of paid and unpaid work.
Results: Societal costs of one single administration of SC trastuzumab were V1753 within the home-
based and V1724 within the hospital-based setting. Drug costs of trastuzumab were identical in both
settings (V1651). Healthcare costs were higher for home-based administration (V91 versus V47) mainly
because of more time of healthcare professionals (110 versus 38 minutes). Costs for patient and family
were, however, lower for home-based administration due to travelling expenses (V7 versus V0) and time
of informal caregivers (V14 versus V4). Costs for productivity losses were similar for both settings.
Conclusions: Home-based subcutaneous administration of trastuzumab is more time consuming for
healthcare professionals and therefore more costly than hospital-based administration. The total budget
impact can be large considering that a large number of patients receive a large number of cycles of
oncology treatments. If home-based administration is the way forward, novel approaches are crucial for
ensuring efficiency of home-based care.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Worldwide, about 2.1 million women are yearly diagnosed with
breast cancer, which is a quarter of all new cancer cases in women
[1]. In 2013, the European Medicines Agency (EMA) approved thenology Assessment. Erasmus
am, the Netherlands.
.
ier Ltd. This is an open access articsubcutaneous (SC) formulation of trastuzumab (Herceptin®) for
patients with HER2þ breast cancer based on similar pharmacoki-
netic, efficacy and safety compared to intravenous (IV) trastuzumab
[2].
Several studies showed high patient satisfaction and prefer-
ences for SC over IV administration within the hospital setting
mainly because of time savings for patients and healthcare pro-
fessionals [3e5]. These time savings resulted in lower healthcare as
well as lower societal costs for SC compared to IV administration
[6e9]. Patient satisfaction and preferences may even be higher inle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the context of the growing pressure on the capacity of oncology
day-care units and healthcare policy of shifting hospital to home-
care, it can be expected that an increasing number of patients will
receive home-based care. A recent systematic review [10] showed,
however, that there is only limited evidence on time investments of
patients and healthcare professionals and the associated costs of
home-based administration of oncology drugs.
The aim of this study was to investigate resource use and time
investments of healthcare professionals, patients and their family
and the associated costs of the SC administration of trastuzumab in
The Netherlands. We compared healthcare and societal costs of one




We conducted an observational non-interventional study using
a bottom-up micro-costing approach, which is the ‘gold standard’
for costing studies [11]. The following three cost categories were
included: i) costs within the healthcare sector including drugs, use
of healthcare facilities, time of healthcare professionals, consum-
ables, and, for home-based administration, travelling expenses of
healthcare professionals; ii) patient and family costs including
travelling expenses of the patients and time of family and/or
friends; and iii) costs in other sectors, in particular costs related to
productivity losses.
2.2. Patient population
Patients were recruited in four hospitals (one academic and
three general hospitals). All four hospitals administrate SC trastu-
zumab at the oncology day-care unit. Two of the four hospitals
provided home-based administration, both on a pilot project basis.
To ensure safe use of trastuzumab, patients only receive home-
based administration by a specialised nurse and after at least one
administration at the day-care unit. One hospital offered this ser-
vice to all patients if they had a preference of home-based over
hospital-based administration and the other hospital offered this
service only to a limited number of patients (at discretion of the
oncologist in consultationwith the patient). One hospital organised
home-based administration by oncology nurses from their day-care
oncology unit, the other outsourced this to two homecare organi-
sations for specialised care. Generally, most patients receive one SC
administration at the hospital (often on the same day they visit the
oncologist) followed by a block of three administrations at home,
which is at the discretion of their oncologist in collaboration with
the patient. The online Supplementary file shows the care path-
ways of both settings.
This study is a follow-up of a study [7] in which we compared
healthcare and societal costs of IV and SC administrationwithin the
hospital setting. Patients were eligible for inclusion if they were 18
years or older and diagnosedwith HER2þ early or metastatic breast
cancer. For this study, we included all patients receiving hospital-
based administration of SC trastuzumab monotherapy (i.e.,
excluding patients of our previous study who received rituximab,
trastuzumab IV, and combination therapy). All patients receiving SC
trastuzumab monotherapy were approached for participation
when they visited the day-care unit at the days of data collection in
the four hospitals. Full details and results of the previous study are
reported elsewhere (Franken et al. [7]). For the home-based setting,
we recruited new patients. All patients receiving SC trastuzumab
monotherapy organised via the two hospitals were approached forparticipation. As we only included patients who received mono-
therapy, we did not have to make a distinction between early and
metastatic breast cancer as SC trastuzumab monotherapy is used
identical in both settings. Informed consent was signed by all
included patients. Ethical approval by the medical ethical com-
mittee was obtained in the participating hospitals.
2.3. Data collection
Data were collected at the hospital pharmacy (preparation of
trastuzumab injection), oncology day-care unit (hospital-based
administration) and at patients’ home (home-based
administration).
Data for healthcare-related costs were collected using case
report forms and questionnaires. Regarding the preparation of the
injection, data were collected at the hospital pharmacy for 20 SC
trastuzumab injections including usage of consumables and time of
healthcare professionals needed for preparation and delivery of
trastuzumab. Regarding the administration of SC trastuzumab, a
case report formwas completed for each patient. This included data
on usage of consumables, time investments of healthcare pro-
fessionals (including ‘non-bedside’ activities such as time for
reporting and administrative tasks), and for home-based adminis-
tration travelling distance and travelling time of the nurse (i.e.,
distance and time from hospital or previous patient to the home of
the patient plus the time from the last patient to the hospital
divided by the number of patients visited). Besides this, each hos-
pital and homecare organisation completed one questionnaire
regarding time investments for related administrative tasks not
included in the case report forms (e.g., time for referral and
reporting between hospital and homecare organisation, time for
scheduling and phone calls to patients).
Data for patient and family costs and productivity losses were
collected using patient questionnaires. These questionnaires
included questions on age, gender, travel distance to hospital, mode
of transportation, paid and unpaid work, sick-leave, and informal
care (friend or family member accompanying the patient). The
questionnaire for home-based administration also included one
question on the expected time of arrival of the nurse (i.e., potential
waiting time) and questions on preference and satisfaction
regarding administration within both settings (i.e., What do you
prefer: hospital- or home-based administration? Why do you
prefer this? Can you give a score between 1 and 10 for your level of
satisfaction for the hospital setting and home-based setting?).
All data were collected between March 25, 2017 and August 10,
2017 for hospital-based and between January 8, 2018 and July 17,
2018 for home-based administration.
2.4. Unit costs and cost analysis
Costs were computed using themethodology as described in the
Dutch costing manual [12,13]. Resource use volumes were multi-
plied with unit prices. Time of healthcare professionals was valued
using wage rates. Unit costs for consumables were provided by the
participating day-care units and, if unavailable, complemented
with market prices. Costs for the preparation of trastuzumab con-
sisted of costs for consumables and the required time of healthcare
professionals measured at the hospital pharmacy. In cases where
trastuzumab was administered by nurses of the homecare organi-
sations, the injection preparation time was included in the total
nurse time at patients’ home (injections are prepared by nurses of
the homecare organisation at a patient’s home). Costs of trastuzu-
mab were obtained from the Z-index (i.e., official Dutch list-price
without VAT), version October 2017.
Reference prices of the Dutch costing manual [12,13] were used
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care. Productivity losses were valued according to the friction-cost
methodology (i.e., absence from work because of illness and/or
treatment restricted to a friction period of 12 weeks; after this
friction period no further productivity costs are incurred as it is
assumed that another worker has fully replaced the person who is
absent due to illness [14]).
Overhead costs for hospital-based administration were deter-
mined using the financial administration of oncology day-care
units (including costs for infrastructure and other facility-
associated costs). The actual time spent on the day-care unit was
multiplied with the unit cost per minute of admission (i.e., V0.76
per minute; see Franken et al. [7] for further details). As patients do
not spent time in the day-care unit in case of home-based admin-
istration and because no data was available for overhead costs of
the homecare organisations, overhead costs related to home-based
administration were determined using information from annual
financial statistics of Dutch Hospital Data [15]. Although these
aggregated data are not specific for the participating hospitals, it
distinguishes different cost categories allowing separating direct
costs and indirect costs relevant to the homecare setting. As such,
we could determine a mark-up percentage on direct costs (i.e.,
19.7%). Overhead costs were then computed by multiplying all
direct costs with this mark-up.
All costs were based on Euro 2017 prices; where necessary unit
costs were adjusted to 2017 prices using the general price index
from the Dutch Central Bureau of Statistics [16]. Table 1 presents
the unit costs. Patient baseline characteristics were summarized
using descriptive statistics. Statistical significance of the differences
between patients receiving home-based and hospital-based
administration was assessed using an independent sample t-test
for age and using Pearson’s chi-square test for the presence of an
informal caregiver, paid and unpaid work.Table 1
Unit costs.
Unit costs (Euro 20
Time of healthcare professionals
Pharmacist V 0.87 per minute
Hospital care: Nurse V 0.56 per minute
Homecare: Nurse V 0.58 per minute
Pharmacy employee V 0.41 per minute
Pharmacy assistant V 0.46 per minute
Hospital: planner V 0.46 per minute
Homecare organisation: planner V 0.39 per minute
Overhead costs
Hospital care: Time spent at day-care unit V 0.76 per minute
Homecare: Overhead mark-up 19.7%
Drug costs (Source: Z-index, Oct. 2017)
Trastuzumab 600 mg (injection) V 1651.41
Societal costs
Reimbursement for travelling distance nurses
Car V 0.30 per km
Travelling expenses patients
Car V 0.19 per km þ V
Public Transport V 0.19 per km
Biking/Walking V 0.00 per km
Informal care costs V 14.32 per hour
Paid work V 32.33 per hour (
Unpaid work V 14.32 per hour
Consumables (per item)
Subcutaneous needles 25 Gauge V 0.11
Blunt fill needle V 0.13
Syringe 5 mL V 0.05
Sterile (non-sterile) gloves (pair) V 0.48 (V 0.06)
Sterile (non-sterile) gauze 5  5 & 10  10 cm V 0.015 (V 0.003) &
Non-sterile protective coating V 0.09
Disinfectant/alcohol wipe V 0.12
Gown & hat V 0.11 & V 0.06All timemeasurement, resource use and costs were reported per
single administration of SC trastuzumab as averages including
standard deviation (SD). As time and cost data are typically skewed
and non-normal distributed, classical hypotheses tests (e.g., Stu-
dent t-test) are not appropriate. Therefore, statistical significance of
the difference in time investment and costs between home-based
and hospital-based administration of SC trastuzumab was
assessed by using non-parametric bootstrap techniques as
described by Desgagne et al. [17] in Microsoft Excel®, version 2013.
Using this method, statistical tests are performed on a large num-
ber of bootstrapped samples (i.e., 1000) which are drawn from the
observed data. All other statistical analyses were conducted using
the statistical software of STATA®, version 14.1 (StataCorp LP. Col-
lege Station, Texas, USA).
3. Results
3.1. Patients
In total 68 female patients were included in the study: 39
received hospital-based and 29 received home-based SC trastuzu-
mab. Participation rate was high, only four out of 72 patients could
not be included in the study. Of these four patients, two patients did
not return the patient questionnaire, one patient could not com-
plete the questionnaire due to a language barrier, and one patient
did not consent for participation. Table 2 presents the patient
characteristics. About three-quarter of the patients within the
home-based setting received the injection by a nurse from the
oncology day-care unit. Informal care givers more often accompa-
nied patients in the hospital setting (49% versus 10%; p ¼ 0.001).
Although relativelymore patients within the hospital-based setting
had paid work (67% versus 48%), most patients were absent of work
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female) Hakkaart et al.
Hakkaart et al.
Financial administration of daycare units
V 0.015 (V 0.007)
Table 2
Patient chararcteristics.
Home-based administration Hospital-based administration p-value *
Number of patients 29 39
Age, mean [SD] 51.6 [14.8] 53.1 [12.0] 0.665
Female 100% 100%
Homecare organisation 24.1% n/a
Accompanying informal caregiver 10.3% 48.7% 0.001
Paid work 48.3% 66.7% 0.128
>12 weeks absent due to illness 85.7% 80.8% 0.695
Unpaid work 16.7% 17.9% 0.896
* Statistical significance of the differences was assessed using an independent sample t-test for age and using Pearson’s chi-square test for the other characteristics.
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3.2. Time measurements and travel distances
Table 3 shows the time measurements of healthcare pro-
fessionals, patients, family and productivity losses and travel dis-
tances. Time investments of healthcare professionals was much
larger for home-based administration (110 versus 38 min;
p ¼ 0.004). This was largely due to travelling time of the nurse
(41 min in the home-based setting) and longer time spend with the
patient (31 min versus 13 min). Patients stayed on average 62 min
at home whereas patients spent 46 min in the hospital (note:
excluding travelling time of the patient). The travelling distance
was somewhat greater for nurses in the home-based setting
(27 km) compared to patients in the hospital-based setting (23 km).
Therewere no productivity losses from paid work, because patientsTable 3
Time measurements for a single SC trastuzumab injection.





Time stayed at home for injection 62.1
Time spent in hospital (arrival to discharge) n/a
Length of stay day-care unit n/a
Hospital
Total Healthcare professional time 110.2
Preparation of trastuzumab
Healthcare professional timea n/aa
Administration of trastuzumab
Responsible nurse 95.9
Bedside activities (time with patient) 30.7
Time with patient 26.0
Duration SC injection 4.7
Non-bedside activities 23.9
Travel time nurse 41.3
Second nurse 1.6
Planner in hospital-based settingb 2.7
Planner in home-based setting 2.0
Referral & reporting (between hospital & homecare organisation) 8.0
Societal
Productivity losses
Paid work (hours) 0.00
Unpaid work (hours) 0.41
Time of informal caregiver (hours) 0.31
Distance patient's home to hospital (kilometers) 15.50
Travelling distance patient (kilometers) n/a
Travelling distance nurse (kilometers) 26.80
SC subcutaneous; SD standard deviation.
a for home-based administration, preparation time of the trastuzumab injection was i
b Costs for the time of a planner were in the hospital-based setting included within th
c Statistical significance of the difference in time was assessed using non-parametric beither had no paid work or were absent fromwork longer than the
12-week friction period. Productivity losses from unpaid workwere
small and comparable between both groups. Time of informal care
givers was almost three times higher within the hospital setting (57
versus 19 min).
3.3. Healthcare and societal costs
Table 4 presents healthcare and societal costs for a single SC
administration of trastuzumab. Drug costs were identical in both
settings (V1651). Administration costs for a single injection
excluding drug costs wereV72.86 for a hospital-based andV101.70
for a home-based administration (difference in costs: V28.84;
p ¼ 0.027). Costs for time of healthcare professionals were three
times higher within the home-based setting (V63.11 versus











62.9 38.3 4.8 71.9 0.004
n/aa 5.8 3.1
49.1 28.7 4.9 67.2 0.001
10.8 12.6 4.9 18.1
10.9 6.2 4.2 19.8
1.9 6.4 1.9 1.7 <0.001
17.3 16.1 12.4 7.7
32.8 n/a n/a
1.0 0.6 0.2 1.0
1.3 3.2 0.9 0.5
3.7 n/a n/a
14.4 n/a n/a
0.00 0.00 0.00 0.00
1.19 0.38 0.88 0.03
0.97 0.94 1.13 0.63
13.34 11.54 8.84 3.96
n/a 23.08 17.68
28.17 n/a n/a
ncluded in costs for ready to use trastuzumab injection.
e overhead costs.
ootstrap techniques (1000 bootstraps).
Table 4
Average healthcare and societal costs for a single SC trastuzumab injection.
Average costs in Euro (2017) Home-based administration (n¼ 29) Hospital-based administration (n¼ 39) Difference P-valuec
Healthcare costs
Active healthcare professional time V 63.11 V 19.52 V 43.59
Preparation of trastuzumaba V - V 2.99 V 2.99
Administration of trastuzumabb V 63.11 V 16.53 V 46.59
Consumables V 6.48 V 2.30 V 4.17
Preparation of trastuzumaba V - V 1.83 V 1.83
Administration of trastuzumab V 6.48 V 0.47 V 6.01
Ready to use trastumuzab injectiona V 6.03 V - V 6.03
Syringes & needles V 0.14 V 0.16 V 0.01
Desinfectant, gauzes, bandages & plasters V 0.15 V 0.13 V 0.02
Protective materials (e.g. gloves, gown, mask) V 0.12 V 0.18 V 0.06
Overhead costs V 13.71 V 25.29 V 11.58
Hospital-based administration: time at day-care unit V 25.29
Home-based administration: mark-up on direct costs V 13.71
Reimbursement of travelling expenses (nurse) V 8.04 V - V 8.04
Subtotal healthcare costs excluding trastuzumab V 91.33 V 47.11 V 44.22 0.001
SD V 46.75 V 29.62
min V 50.20 V 23.71
max V 272.36 V 181.75
Trastuzumab V 1651.41 V 1651.41 V -
Subtotal healthcare costs including trastuzumab V 1742.74 V 1698.52 V 44.22
Societal costs
Travelling expenses patient V - V 6.72 V 6.72
Time of informal caregiver V 4.44 V 13.52 V 9.08
Productivity losses
Paid work V - V - V -
Unpaid work V 5.93 V 5.51 V 0.42
Subtotal societal costs V 10.37 V 25.75 V -15.38 0.008
SD V 20.66 V 24.80
min V - V -
max V 71.60 V 98.53
Total costs for a single SC administration
Excluding trastuzumab V 101.70 V 72.86 V 28.84 0.027
SD V 55.93 V 46.14
MIN V 50.20 V 29.79
MAX V 272.36 V 222.96
Including trastuzumab V 1753.11 V 1724.27 V 28.84
SD V 55.93 V 46.14
MIN V 1701.61 V 1681.20
MAX V 1923.77 V 1874.37
SC subcutaenous; SD standard deviation; MIN minimum observed costs; MAX maximum observed cost.
a For home-based administration, costs for the preparation of the injection related to the time of healthcare professionals and usage of consumables were included in costs
for ready to use trastuzumab injection.
b Costs of adminstrative staff (planner) in the hospital setting were included in the overhead costs (thus not in the active time of healthcare professionals).
c Statistical significance of the difference in costs was assessed using non-parametric bootstrap techniques (1000 bootstraps).
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were higher for home-based administration (V91.33 versus V47.11;
p ¼ 0.001), societal costs were higher for hospital-based adminis-
tration (V25.75 versus V10.37; p ¼ 0.008). This was partly related
to a shift from societal costs in the hospital-based setting to
healthcare costs in the home-based setting due to travelling ex-
penses (i.e., out-of-pocket expenses for patients shifted to costs for
healthcare). The remainder of the difference was due to the greater
time informal care givers accompanied patients within the
hospital-based setting, resulting in higher (societal) costs of
informal care compared to the home-based setting (V13.52 versus
V4.44).4. Discussion
We investigated resource use and time investments of health-
care professionals, patients, family and productivity losses and the
associated costs of the administration of SC injections of trastuzu-
mab. Our study showed that home-based SC administration of
trastuzumab costs more than hospital-based administration. Costsfor healthcare are higher for home-based administration as it re-
quires more time of healthcare professionals. Costs for patient and
family were, however, lower for home-based administration due to
travelling expenses and time of informal care givers.
Previous studies showed high patient satisfaction and prefer-
ences for SC over IV administration and lower costs for SC admin-
istration [3e9]. The shift to home-based SC administrations of
trastuzumab is, however, relatively new in The Netherlands [18].
The two hospitals that provided home-based administration,
considered this to be of great added value for patients as it is less
intensive for patients. Other reasons for providing home-based
administration were limited capacity of the oncology day-care
unit, collaboration of care across healthcare settings, and requests
from patients as well as market authorisation holders. However,
home-based administration within these hospitals was provided
on a pilot project basis and it should be noted that hospitals do not
receive earmarked funding for home-based administration.
To our knowledge, there is limited evidence on healthcare and
societal costs of home-based SC administration of oncology drugs.
A recent systematic review [10] identified two studies [19,20]
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bortezomib for Multiple Myeloma. In contrast to our study, both
studies reported higher costs for hospital-based administration.
Both studies, however, calculated costs using flat rates and/or DRG
tariffs (e.g., a flat rate for admission day-care unit). In contrast, we
conducted a bottom-up micro-costing study and based the costs on
the actual measured time of healthcare professionals, usage of
consumables, time spent at the day-care unit, and time of informal
care givers. Therefore, our cost estimates are more accurate as they
are based on actual consumption of healthcare professional time
and resources instead of using flat rates (e.g., negotiated prices)
identical for every patient irrespective of actual consumption. A
bottom-up micro-costing approach can be considered as the ‘gold
standard’ for costing studies [11].
It should be noted that our study has some limitations. First, it
was impossible to use an identical method for determining over-
head costs in both settings. The method used for hospital-based
administration is the most preferred method as overhead costs
were calculated using financial data of the participating day-care
units. This was, however, not possible for home-based adminis-
tration because i) patients do not occupy a hospital bed for home-
based administration, and ii) such data were not available. There-
fore, we used a generic mark-up on direct costs for the home-based
setting. As overhead costs are accountable for 40% of the difference
in costs between hospital-based and home-based administration,
wemay either have under- or overestimated the difference in costs.
For example, if we would have used a mark-up of 30% or 40%
instead of 19.7%, the overhead costs for home-based administration
would be V20.88 and V27.83 instead of V13.71, respectively. This
would increase the difference in costs between home-based and
hospital-based administration from V28.84 to V36.02 and V42.97,
respectively. Second, some of the differences may be due to the
relatively small sample size and the observational nature of our
study as patients received care as usual and were not randomly
assigned to either hospital-based or home-based administration.
Although other observational studies successfully applied statisti-
cal techniques to improve comparability of patient groups, essential
prerequisites [21], such as large patient numbers and (information
on) valid predictors for costing items, were missing in our study.
Even though our study was conducted in The Netherlands and
only included a small number of patients, we believe that our study
provides important new information which may have implications
for healthcare professionals, hospitals, healthcare decision makers
and healthcare payers in other countries. As we observed that the
differences in costs were mostly related to the additional time of
the nurse in the home-based setting (more time with the patient as
well as time for travelling), we believe that these findings are
transferable to other countries irrespective of the healthcare
context. Larger studies and studies in other countries are necessary
as cost information on home-based administration is highly rele-
vant because of preferences, high patient satisfaction, and the
growing pressure on the capacity of oncology day-care units. Our
study confirmed that patients were more satisfied with home-
based administration (satisfaction score of 9.2 versus 8.4 on a
scale of 10). It should be noted that this score may be influenced by
selection bias as this question was only included in the patient
questionnaire within the home-based setting (i.e. patients with a
preference for home-based administration). Our study also
revealed that costs are higher for home-based administrations,
mainly because time investments of healthcare professionals
almost tripled in our study. Most of the greater time investments of
healthcare professionals were related to activities which are non-
existing in a hospital setting irrespectively of the context of the
country. The actual injection time of SC trastuzumab and subse-
quent time for observation should not deviate between countries asit is set down in the product label. Active nurse time for observation
post injection can be lower in any hospital setting because of
possible nurse activities for other patients during the observation
period. If in the future patients would be able to safely self-
administer SC trastuzumab, for example using a single-use injec-
tion device, costs could decrease as long as the costs for such a
device would not be larger than the current costs for the time of
healthcare professionals. Although travelling distance, time, and
unit costs for the time of healthcare professionals is context spe-
cific, our detailed breakdown of unit costs and resource use allows
easy adaptation of our findings to other settings.
The greater time investments of healthcare professionals and its
financial consequences could be a reason that hospitals are reluc-
tant for providing home-based administration. Furthermore, our
study illustrated the importance of comparing healthcare and so-
cietal costs as we observed a shift from societal to healthcare costs.
This is relevant as hospitals and healthcare payers are, in The
Netherlands, not financially responsible for societal costs such as
travelling expenses of the patients, costs of informal care and
productivity losses. Consequently, there is a financial disincentive
for home-based administration.
More importantly, administration costs are only a small part of
the total costs for oncology care. Regarding the high drug costs,
although negotiated drug prices remain confidential, potentially
much larger savings can be achieved by switching to, most likely
less costly, biosimilar equivalents. The biosimilar equivalents are,
however, for the coming years only available for IV infusion (either
hospital-based or home-based). Nonetheless, although our previ-
ous study [7] showed that IV administration is more expensive than
SC administration within the hospital setting (difference for one
administration in healthcare costs: V68 and societal costs V22), IV
administration within the hospital setting would be less expensive
in case drug costs of IV trastuzumab (-biosimilar) would decrease
by 8% or more compared to drug costs of SC administration of
trastuzumab. This underlines the dilemma between the pressure
on the capacity of oncology day-care units, preferences for SC over
IV administration, preferences for home-based over hospital-based
administration, and the costs of the different strategies. It is,
therefore, crucial to focus on novel and efficient approaches of
hospital-based and home-based care.
In conclusion, this study shows that home-based SC adminis-
tration of trastuzumab is more time consuming for healthcare
professionals and therefore more costly than hospital-based
administration. Although the impact seems rather limited consid-
ering the absolute costs for one single administration, the budget
impact can be large considering the large number of patients who
receive a large number of treatment cycles. Notwithstanding the
preferences for home-based care and the reduction of the pressure
on the capacity of oncology day-care units, if home-based care is
the way forward, novel approaches are vital for ensuring efficiency
of home-based care.
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